One variation of a method includes, during a calibration period: triggering collection of an initial bioaerosol sample by an air sampler located in an environment; and triggering dispensation of a tracer test load by a dispenser located in the environment; accessing a detected barcode level of a barcode detected in the initial bioaerosol sample; accessing a true barcode level of the barcode contained in the tracer test load; and deriving a calibration factor for the environment based on a difference between the detected barcode level and the true barcode level. The method further includes, during a live period succeeding the calibration period: triggering collection of a first bioaerosol sample by the air sampler; accessing a detected pathogen level of a pathogen detected in the first bioaerosol sample; and interpreting a predicted pathogen level of the pathogen in the environment based on the detected pathogen level and the calibration factor.

The present invention relates to methods of detecting an infection in a subject based on the relative abundance of target molecules indicative of the expression of at least the gene pair DUSP1 and IFI27. In particular, the invention relates to a method of distinguishing between a bacterial infection or a non-bacterial infection in a subject, especially between bacterial and non-bacterial lower respiratory system infections using the gene pair. Further, the invention provides the medical use of therapeutic agents in the treatment of a bacterial or non-bacterial infection in a subject identified as having such an infection through use of a method of the invention, and monitoring the therapeutic effectiveness.

The present invention relates to methods of detecting an infection in a subject based on the relative abundance of target molecules indicative of the expression of at least the gene pair DUSP1 and IFI27. In particular, the invention relates to a method of distinguishing between a bacterial infection or a non-bacterial infection in a subject, especially between bacterial and non-bacterial lower respiratory system infections using the gene pair. Further, the invention provides the medical use of therapeutic agents in the treatment of a bacterial or non-bacterial infection in a subject identified as having such an infection through use of a method of the invention, and monitoring the therapeutic effectiveness.

One variation of a method includes, during a calibration period: triggering collection of an initial bioaerosol sample by an air sampler located in an environment; and triggering dispensation of a tracer test load by a dispenser located in the environment; accessing a detected barcode level of a barcode detected in the initial bioaerosol sample; accessing a true barcode level of the barcode contained in the tracer test load; and deriving a calibration factor for the environment based on a difference between the detected barcode level and the true barcode level. The method further includes, during a live period succeeding the calibration period: triggering collection of a first bioaerosol sample by the air sampler; accessing a detected pathogen level of a pathogen detected in the first bioaerosol sample; and interpreting a predicted pathogen level of the pathogen in the environment based on the detected pathogen level and the calibration factor.

One variation of a method includes, during a calibration period: triggering collection of an initial bioaerosol sample by an air sampler located in an environment; and triggering dispensation of a tracer test load by a dispenser located in the environment; accessing a detected barcode level of a barcode detected in the initial bioaerosol sample; accessing a true barcode level of the barcode contained in the tracer test load; and deriving a calibration factor for the environment based on a difference between the detected barcode level and the true barcode level. The method further includes, during a live period succeeding the calibration period: triggering collection of a first bioaerosol sample by the air sampler; accessing a detected pathogen level of a pathogen detected in the first bioaerosol sample; and interpreting a predicted pathogen level of the pathogen in the environment based on the detected pathogen level and the calibration factor.

One variation of a method for detecting pathogens includes: accessing a timeseries of pathogen data for a pathogen, in a set of pathogens, derived from a series of pathogen samples collected in an environment during a time period; characterizing a pathogen profile, representative of changes in pathogen level of the first pathogen in the environment during the time period, based on the timeseries of pathogen data; accessing a baseline pathogen profile representative of changes in pathogen levels of the set of pathogens in the environment during an initial time period preceding the time period; characterizing a difference between the pathogen profile and the baseline pathogen profile; and, in response to the difference exceeding a threshold difference, selecting a mitigation action configured to reduce pathogen levels of the first pathogen and transmitting a prompt to execute the mitigation action to a user associated with the indoor environment.

One variation of a method for detecting pathogens includes: accessing a timeseries of pathogen data for a pathogen, in a set of pathogens, derived from a series of pathogen samples collected in an environment during a time period; characterizing a pathogen profile, representative of changes in pathogen level of the first pathogen in the environment during the time period, based on the timeseries of pathogen data; accessing a baseline pathogen profile representative of changes in pathogen levels of the set of pathogens in the environment during an initial time period preceding the time period; characterizing a difference between the pathogen profile and the baseline pathogen profile; and, in response to the difference exceeding a threshold difference, selecting a mitigation action configured to reduce pathogen levels of the first pathogen and transmitting a prompt to execute the mitigation action to a user associated with the indoor environment.

This application provides methods, kits, probes and primers, that can be used to analyze environmental samples, such as water samples, soil samples, and air samples. The methods and kits can include positive controls, to provide confidence in test results.

This application provides methods, kits, probes and primers, that can be used to analyze environmental samples, such as water samples, soil samples, and air samples. The methods and kits can include positive controls, to provide confidence in test results.

Various embodiments are directed to applications (e.g., classification of biological samples) of the analysis of the count, the fragmentation patterns, and size of cell-free nucleic acids, e.g., plasma DNA and serum DNA, including nucleic acids from pathogens, such as viruses. Embodiments of one application can determine if a subject has a particular condition. For example, a method of present disclosure can determine if a subject has cancer or a tumor, or other pathology. Embodiments of another application can be used to assess the stage of a condition, or the progression of a condition over time. For example, a method of the present disclosure may be used to determine a stage of cancer in a subject, or the progression of cancer in a subject over time (e.g., using samples obtained from a subject at different times).